Inhibrx Institutionelles Eigentum
Was ist das Institutionelles Eigentum von Inhibrx?
Institutionelles Eigentum von Inhibrx, Inc. ist 80.27%
Was ist die Definition von Institutionelles Eigentum?
Institutionelles Eigentum ist der Betrag der verfügbaren Aktien eines Unternehmens, das sich im Besitz von Investmentfonds oder Pensionskassen, Versicherungsgesellschaften, Wertpapierfirmen, Stiftungen oder anderen großen Körperschaften befindet, die Fonds für Dritte verwalten.
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
Institutionelles Eigentum von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Inhibrx
Was macht Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Unternehmen mit institutionelles eigentum ähnlich Inhibrx
- Stock Spirits Plc hat Institutionelles Eigentum von 80.16%
- SVMK Inc hat Institutionelles Eigentum von 80.18%
- Freeport-McMoRan Inc hat Institutionelles Eigentum von 80.20%
- Marathon Oil hat Institutionelles Eigentum von 80.20%
- ULS Technology plc hat Institutionelles Eigentum von 80.22%
- Target Corp hat Institutionelles Eigentum von 80.26%
- Inhibrx hat Institutionelles Eigentum von 80.27%
- Marathon Oil hat Institutionelles Eigentum von 80.28%
- Marathon Oil hat Institutionelles Eigentum von 80.28%
- BlackRock hat Institutionelles Eigentum von 80.28%
- BlackRock hat Institutionelles Eigentum von 80.28%
- RCF Acquisition hat Institutionelles Eigentum von 80.29%
- Carriage Services hat Institutionelles Eigentum von 80.29%